Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles

碩士 === 國立中正大學 === 化學工程所 === 98 === The anticancer drugs, carmustine (BCNU) and doxorubicin (Dox), entrapped by solid lipid nanoparticles (SLNs) were used in this study. SLN lipid matrix was composed of cacao butter (CB), stearic acid (SA). SLN liquid phase contained equal molar ratio of hexadecylt...

Full description

Bibliographic Details
Main Authors: cheng-te liang, 梁正德
Other Authors: none
Format: Others
Language:zh-TW
Published: 2010
Online Access:http://ndltd.ncl.edu.tw/handle/91358404686583160778
id ndltd-TW-098CCU05063094
record_format oai_dc
spelling ndltd-TW-098CCU050630942015-10-13T18:25:49Z http://ndltd.ncl.edu.tw/handle/91358404686583160778 Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles 包覆carmustine及doxorubicin的陰陽離子型固態脂質奈米粒子對抑制人類惡性神經膠質瘤U87MG細胞的效應 cheng-te liang 梁正德 碩士 國立中正大學 化學工程所 98 The anticancer drugs, carmustine (BCNU) and doxorubicin (Dox), entrapped by solid lipid nanoparticles (SLNs) were used in this study. SLN lipid matrix was composed of cacao butter (CB), stearic acid (SA). SLN liquid phase contained equal molar ratio of hexadecyltrimethylammonium bromide (HTMAB) and sodium dodecyl sulphate (SDS) to form catanionic surfactant mixture. The smallest nanopaticle diameter was abtained at 1 mM catanionic surfactant. The maximum entrapment efficiency of BCNU-SLN was 81%, Dox-SLN was 61%. Moreover, XPS analysis data was shown that equal molar ratio of nitrogen and sulfur element on SLN surface. Furthermore, cell growth inhibition of glioblastma U87MG by BCNU-SLN and Dox-SLN results the decrease of epidermal growth factor receptor expression while time increased. We considered that U87MG was inhibited by drug carrier. none 郭勇志 2010 學位論文 ; thesis 87 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立中正大學 === 化學工程所 === 98 === The anticancer drugs, carmustine (BCNU) and doxorubicin (Dox), entrapped by solid lipid nanoparticles (SLNs) were used in this study. SLN lipid matrix was composed of cacao butter (CB), stearic acid (SA). SLN liquid phase contained equal molar ratio of hexadecyltrimethylammonium bromide (HTMAB) and sodium dodecyl sulphate (SDS) to form catanionic surfactant mixture. The smallest nanopaticle diameter was abtained at 1 mM catanionic surfactant. The maximum entrapment efficiency of BCNU-SLN was 81%, Dox-SLN was 61%. Moreover, XPS analysis data was shown that equal molar ratio of nitrogen and sulfur element on SLN surface. Furthermore, cell growth inhibition of glioblastma U87MG by BCNU-SLN and Dox-SLN results the decrease of epidermal growth factor receptor expression while time increased. We considered that U87MG was inhibited by drug carrier.
author2 none
author_facet none
cheng-te liang
梁正德
author cheng-te liang
梁正德
spellingShingle cheng-te liang
梁正德
Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
author_sort cheng-te liang
title Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
title_short Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
title_full Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
title_fullStr Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
title_full_unstemmed Inhibition of U87MG cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
title_sort inhibition of u87mg cell growth by carmustine and doxorubicin entrapped catanionic solid lipid nanoparticles
publishDate 2010
url http://ndltd.ncl.edu.tw/handle/91358404686583160778
work_keys_str_mv AT chengteliang inhibitionofu87mgcellgrowthbycarmustineanddoxorubicinentrappedcatanionicsolidlipidnanoparticles
AT liángzhèngdé inhibitionofu87mgcellgrowthbycarmustineanddoxorubicinentrappedcatanionicsolidlipidnanoparticles
AT chengteliang bāofùcarmustinejídoxorubicindeyīnyánglízixínggùtàizhīzhìnàimǐlìziduìyìzhìrénlèièxìngshénjīngjiāozhìliúu87mgxìbāodexiàoyīng
AT liángzhèngdé bāofùcarmustinejídoxorubicindeyīnyánglízixínggùtàizhīzhìnàimǐlìziduìyìzhìrénlèièxìngshénjīngjiāozhìliúu87mgxìbāodexiàoyīng
_version_ 1718032402534629376